- Global Pharma News & Resources

Global Biologics Market Forecasts From 2018 to 2023 -

The "Global Biologics Market - Forecasts From 2018 to 2023" report has been added to's offering.

The global biologics market is expected to reach US$310.776 billion by 2023 from US$236.121 billion in 2017, growing at a CAGR of 4.69%.

The biologics market is expected to show significant growth during the given forecast period owing to the growing capital investments from key market players. Recently in Oct 2018, Merck announced the building of second manufacturing plant for vaccines and biologics in Ireland due to growing demand for the company's medicines and vaccines.

Growing adoption of the innovative therapies for the treatment of various disorders will also augment the growth of the market during the forecast period. However, stringent regulatory requirements for the market approval of biologics might restrain the market for biologics during the given time frame.

Key Topics Covered

1. Introduction

2. Research Methodology

3. Key Findings of the Study

4. Market Dynamics

4.1. Drivers

4.2. Restraints

4.3. Opportunities and Market Trends

4.4. Market Segmentation

4.5. Porter's Five Forces Analysis

4.6. Industry Value Chain Analysis

4.7. Industry Regulations

4.8. Scenario Analysis

5. Global Biologics Market Forecast by Type

5.1. Monoclonal Antibodies

5.2. Vaccines

5.3. Recombinant Proteins

5.4. Gene Therapy

5.5. Others

6. Global Biologics Market Forecast by Application

6.1. Oncology

6.2. Neurology

6.3. Orphan Indications

6.4. Infectious Diseases

6.5. Others

7. Global Biologics Market Forecast by Geography

7.1. North America

7.2. South America

7.3. Europe

7.4. Middle East and Africa

7.5. Asia Pacific

8. Competitive intelligence

8.1. Market Share Analysis

8.2. Strategies of Key Players

8.3. Recent Investments and Deals

9. Company Profiles

9.1. F. Hoffmann-La Roche Ltd.

9.2. Amgen Inc.

9.3. AbbVie Inc.

9.4. Novo Nordisk AS

9.5. Johnson & Johnson

9.6. Shire PLC

9.7. Gilead Sciences

9.8. Alexion Pharmaceuticals

9.9. Samsung Biologics

9.10. UCB

For more information about this report visit

View source version on

Editor Details

Last Updated: 20-Dec-2018